# **CONTENTS**

Declaration by the candidate	i
Certificate by the head of department	ii
Certificate by the supervisor	iii
Acknowledgement	iv
List of tables	v
List of figures	vi
List of abbreviation	vii
Content	viii
Chapter no.	Name of the chapter
CHAPTER 1	INTRODUCTION
CHAPTER 2	REVIEW OF LITERATURE
CHAPTER 3	MATERIALS AND METHODS
CHAPTER 4	RESULTS AND DISCUSSION
CHAPTER 5	CONCLUSION

## References

## **LIST OF TABLES**

Table1:Some commercially available iron oxide based magnetic contrast agents.

Table2:All FePt sample

Table3:Edx of samplep1

Table4:Edx of sample s1

Table 5: XRD analysis of the sample.

Table 6: FTIR peak identification from FTIR analysis.

**Table 5:** Data from M-H plot

### **LIST OF FIGURES**

Fig1:reduction of MTT to formazan

Fig 2: EDX sectra of sample p1.

Fig 3:EDX spectra of sample s1

Fig 4:UV-Visible spectra of sample p1.

Fig 5: Photoluminescence spectra of sample p1.

Fig 6: XRD of synthesized samples p1, p2, p3.

Fig7: micrograph of sample p1.

Fig8: micrograph of sample p1.

Fig 9: FTIR spectra of sample p1.

Fig 10: M-H curve of sample p1.

**Fig11:**Viability of lymphocytec in the presence of different concentration of sample p1 nanoparticles.

**Fig. 12:** Viability of lymphocytes in the presence of different concentration of sample p2 nanoparticles.

Fig 13: Viability of lymphocytes in the presence of different concentration of sample p3 nanoparticle

### **LIST OF ABBREVIATIONS**

MRI: Magnetic Resonance Imaging.

NMRI: Nuclear Magnetic Resonance imaging.

**RES:**Reticuloendothelial system.

**EDX:** Energy Dispersive x-ray spectroscopic.

**UV:** Ultra Violet visible spectroscopic.

PL: Photoluminiscence.

**SEM:** Scanning electron microscope.

**XRD:** X-ray diffraction.

FTIR: Fourier Transform Infrared Spectroscopy.

PBS: Phosphate Buffered Saline.

MTT: 3(4,5-dimethyl-2-yl)-2-5 diphenyl tetrazolium bromide.

**DMSO:** Dimethyl sulphoxide.